Oculis Holding AGNASDAQ:OCS
- LAST PRICE11.6250
- TODAY'S CHANGE (%)0.1750 (1.5284%)
- Bid / Lots4.7300/ 1
- Ask / Lots13.0000/ 4
- Open / Previous Close11.7000 / 11.4500
- Day Range
- 52 Week Range
- Volume5,933
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OCS |
|---|---|---|
| 09:41 ET | 1816 | 11.7028 |
| 10:10 ET | 382 | 11.7 |
| 10:32 ET | 165 | 11.575 |
| 10:57 ET | 2295 | 11.6 |
| 11:11 ET | 100 | 11.61 |
| 02:29 ET | 150 | 11.63 |
| 03:45 ET | 100 | 11.625 |
Jun 27, 2024
Oculis and EURETINA Announces the Ramin Tadayoni Award, from 6:30AM ET on Thursday Jun 27, 2024 by Dow Jones
6:30AM ET on Thursday Jun 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oculis Holding AG | 531.8M | -6.2x | --- |
Larimar Therapeutics Inc | 601.0M | -9.8x | --- |
Eliem Therapeutics Inc | 594.4M | -16.2x | --- |
Corbus Pharmaceuticals Holdings Inc | 592.6M | -8.3x | --- |
Allogene Therapeutics Inc | 606.4M | -1.7x | --- |
Cassava Sciences Inc | 611.7M | -12.8x | --- |
Company Information
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Contact Information
- Headquarters
- Bahnhofstrasse 7ZUG, ZUG, Switzerland 6300
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Anthony Rosenberg
- Chief Executive Officer, Director
- Riad Sherif
- Chief Financial Officer
- Sylvia Cheung
- Head - Medical Affairs
- Joanne Chang
- Head - Development
- Bastian Dehmel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $531.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 46.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.87 |
Book Value | $2.90 |
P/E Ratio | -6.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
